



Clinical trial results:

A Randomised, Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy

Summary

EudraCT number	2006-002801-30
Trial protocol	BE CZ HU DE IT ES
Global end of trial date	30 December 2010

Results information

Result version number	v1 (current)
This version publication date	14 November 2018
First version publication date	14 November 2018

Trial information

Trial identification

Sponsor protocol code	ABA-01
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00418574
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Menarini Ricerche S.p.A
Sponsor organisation address	Via Sette Santi, 1, Florence, Italy, 50131
Public contact	Corporate Director, Clinical Sciences, Menarini Ricerche, S.p.A, Corporate Director, Clinical Sciences, Menarini Ricerche, S.p.A, 39 05556809990, acapriati@menarini-ricerche.it
Scientific contact	Corporate Director, Clinical Sciences, Menarini Ricerche, S.p.A, Corporate Director, Clinical Sciences, Menarini Ricerche, S.p.A, 39 05556809990, acapriati@menarini-ricerche.it

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 July 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 December 2006
Global end of trial reached?	Yes
Global end of trial date	30 December 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate benefit in terms of recurrence free survival (RFS) of Abagovomab versus placebo as maintenance therapy after clinical complete response (CR) to debulking surgery and standard platinum/taxane first line chemotherapy in patients with epithelial, CA125 expressing, advanced (FIGO stage III-IV) ovarian cancer.

Protection of trial subjects:

If any event(s) related to the conduct of the study or the development of the IMP affected the safety of the study participants, the Sponsor and the investigator would have taken appropriate urgent safety measures to protect the subjects against any immediate hazard. The CA and IRB/EC would have been informed forthwith about these new events and the measures taken. For subjects participating in the study, Menarini Ricerche S.p.A. stipulated an insurance policy in accordance with local regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 December 2006
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	7 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 138
Country: Number of subjects enrolled	Poland: 78
Country: Number of subjects enrolled	Spain: 103
Country: Number of subjects enrolled	Belgium: 23
Country: Number of subjects enrolled	Czech Republic: 82
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	Germany: 299
Country: Number of subjects enrolled	Hungary: 25
Country: Number of subjects enrolled	Italy: 137
Worldwide total number of subjects	888
EEA total number of subjects	750

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	675
From 65 to 84 years	213
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study population was recruited in 139 sites (Hospitals/University Clinics) distributed in Europe (Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland and Spain) and US.

Date of first patient randomised: 08 December 2006 Date of last patient randomised: 26 December 2008

Pre-assignment

Screening details:

Screening and randomisation by IVRS (Interactive Voice Recognition System) had to be performed and completed within 12 weeks from the completion of the last cycle of standard platinum/taxane chemotherapy with documented clinical CR. Patients who met all the inclusion and none of the exclusion criteria were randomised through

Period 1

Period 1 title	DBO (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Abagovomab
------------------	------------

Arm description:

Biological/Vaccine 2m/ml sc

Arm type	Experimental
Investigational medicinal product name	Abagovomab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)

Arm title	Placebo
------------------	---------

Arm description:

Biological/vaccine 2mg/ml sc

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)

Number of subjects in period 1	Abagovomab	Placebo
Started	593	295
Completed	545	272
Not completed	48	23
AE, withdrew consent, protocol violation, DLT...	48	-
AE, withdrew consent, protocol violation, DLT ...	-	23

Baseline characteristics

Reporting groups

Reporting group title	Abagovomab
Reporting group description: Biological/Vaccine 2m/ml sc	
Reporting group title	Placebo
Reporting group description: Biological/vaccine 2mg/ml sc	

Reporting group values	Abagovomab	Placebo	Total
Number of subjects	593	295	888
Age categorical			
Units: Subjects			
<= 18 years	1	0	1
Between 18 and 65 years	447	227	674
>= 65 years	145	68	213
Age continuous			
Units: years			
arithmetic mean	56.4	56.0	-
standard deviation	± 10.57	± 10.47	-
Gender categorical			
Units: Subjects			
Female	593	295	888
Male	0	0	0
Histology of ovaian tumor			
Units: Subjects			
Serous/papillary	481	245	726
Endometrioid	38	21	59
Mucinous	6	3	9
Undifferentiated	14	7	21
Mixed tumor	18	7	25
Others	33	12	45
missing	3	0	3
Eastern Cooperative Oncology Group Performance Status (ECOG-PS)			
Units: Subjects			
ECOG- PS 0	460	240	700
ECOG- PS 1	131	55	186
ECOG- PS 2	2	0	2
Grade of histologic differentiation			
Units: Subjects			
G1-G2	160	82	242
G3-G4	365	185	550
GX	12	4	16
not done	56	24	80
International Federation of Gynecology and Obstetrics (FIGO)			
Units: Subjects			

III	513	252	765
IV	80	42	122
missing	0	1	1
Tumor size after debulking surgery			
Units: Subjects			
<= 1cm	479	232	711
> 1cm	114	63	177
Serum CA-125 3rd chemotherapy cycle			
Units: Subjects			
<= 35U/ml	479	239	718
> 35 U/ml	114	55	169
missing	0	1	1

End points

End points reporting groups

Reporting group title	Abagovomab
Reporting group description:	
Biological/Vaccine 2m/ml sc	
Reporting group title	Placebo
Reporting group description:	
Biological/vaccine 2mg/ml sc	

Primary: Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)

End point title	Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)
End point description:	The Recurrence free survival correspond to the time from date of randomization to documented disease recurrence or death. Disease recurrence is defined as the appearance of any lesion or development of tumor-related symptoms evaluated by medical examination and must be confirmed by a documented CT scan
End point type	Primary
End point timeframe:	Every 12 weeks up to recurrence or up to 3 months after last administered dose

End point values	Abagovomab	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	593	295		
Units: days				
median (confidence interval 95%)				
Recurrence Free Survival Evaluated	403 (323 to 414)	402 (323 to 487)		

Statistical analyses

Statistical analysis title	Statistical Analysis Overview
Comparison groups	Abagovomab v Placebo
Number of subjects included in analysis	888
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.301
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	1.099

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.919
upper limit	1.315

Secondary: Overall Survival

End point title	Overall Survival
End point description: 2 years survival rate	
End point type	Secondary
End point timeframe: 2 years	

End point values	Abagovomab	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	593	295		
Units: Percentage of participants				
number (not applicable)	80	79		

Statistical analyses

No statistical analyses for this end point

Secondary: Safety

End point title	Safety
End point description: Safety was analyzed in all patients who received at least 1 dose administration. Adverse event (AE) are defined as events which started on or after the first dose of study medication and on or before the date of the final study visit, or within 12 weeks of the last dose if the final study visit was not performed.	
End point type	Secondary
End point timeframe: Along treatment administration and up to double blind observation period. i.e. for each patient after the first dose administration till the final study visit, or within 12 weeks of the last dose	

End point values	Abagovomab	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	592	294		
Units: participants				
number (not applicable)				
Patients with at least 1 Adverse Event (AE)	564	278		
Patients with at least 1 Adverse Drug Reaction ADR	507	246		
Patients with at least 1 Serious Adverse Event SAE	141	72		
Patients with at least 1 Serious ADR (SADR)	10	3		
Patients with at least 1 AE leading to withdrawal	93	57		
Patients with at least 1 AE resulted in death	8	4		

Statistical analyses

No statistical analyses for this end point

Secondary: Time Course of Immunoresponse

End point title	Time Course of Immunoresponse ^[1]
End point description:	
Time course of immunologic parameters (anti-anti-idiotypic antibody - Ab3) will be assessed in all patients, by comparing levels at baseline (week 0), at week 10 after first dose administration and at end of treatment (at week 4 or week 12 after the last administered dose, as appropriate)	
End point type	Secondary
End point timeframe:	
At baseline, at week 10 after first dose administration and at final study visit (at week 4 or week 12 after the last administered dose, as appropriate)	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No expected immune response for placebo injection

End point values	Abagovomab			
Subject group type	Reporting group			
Number of subjects analysed	576			
Units: ng/ml				
median (full range (min-max))				
Ab3 (baseline)	0 (0 to 118000)			
Ab3 (week 10)	63550 (0 to 777000)			
Ab3 (end of treatment)	493000 (0 to 2720000)			

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

4 years

Adverse event reporting additional description:

Adverse Events monitored throughout the observation period, at each visit prior dosing (every 2 weeks during the induction phase, every 4 weeks during the maintenance phase)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.1
--------------------	------

Reporting groups

Reporting group title	Abagovomab
-----------------------	------------

Reporting group description:

2 mg/ml SC, every 2 weeks (for the first 4 doses - induction phase) and then every 4 weeks (maintenance phase)

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Serious adverse events	Abagovomab	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	141 / 592 (23.82%)	72 / 294 (24.49%)	
number of deaths (all causes)	171	80	
number of deaths resulting from adverse events	9	4	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bone neoplasms benign (excl cysts)			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine neoplasms malignant and unspecified NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal neoplasms malignant NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Metastases to specified sites			
subjects affected / exposed	14 / 592 (2.36%)	13 / 294 (4.42%)	
occurrences causally related to treatment / all	0 / 16	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasms malignant site unspecified NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasms unspecified malignancy and site unspecified NEC			
subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system neoplasms unspecified malignancy NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-small cell neoplasms malignant of the respiratory tract cell type specified			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oncologic complications and emergencies			
subjects affected / exposed	1 / 592 (0.17%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian neoplasms malignant (excl germ cell)			
subjects affected / exposed	61 / 592 (10.30%)	41 / 294 (13.95%)	
occurrences causally related to treatment / all	0 / 80	0 / 46	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal neoplasms malignant			

subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin neoplasms malignant and unspecified (excl melanoma)			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal neoplasms malignant			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Accelerated and malignant hypertension			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aortic embolism and thrombosis			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphangiopathies			
subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoedemas			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-site specific embolism and thrombosis			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Peripheral embolism and thrombosis subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Device issues NEC subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile disorders subjects affected / exposed	3 / 592 (0.51%)	2 / 294 (0.68%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
General signs and symptoms NEC subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hernias NEC subjects affected / exposed	2 / 592 (0.34%)	2 / 294 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injection site reactions subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema NEC subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain and discomfort NEC subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Therapeutic and nontherapeutic responses			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Allergic conditions NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Breast disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic prolapse conditions			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Breathing abnormalities			
subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumothorax and pleural effusions NEC			
subjects affected / exposed	7 / 592 (1.18%)	5 / 294 (1.70%)	
occurrences causally related to treatment / all	0 / 9	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary thrombotic and embolic conditions			

subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Anxiety symptoms			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depressive disorders			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Digestive enzymes			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function analyses			
subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal function analyses			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skeletal and cardiac muscle analyses			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tissue enzyme analyses NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural			

complications			
Abdominal injuries NEC			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower limb fractures and dislocations			
subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-site specific injuries NEC			
subjects affected / exposed	3 / 592 (0.51%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-site specific procedural complications			
subjects affected / exposed	7 / 592 (1.18%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	1 / 8	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pelvic fractures and dislocations			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal fractures and dislocations			
subjects affected / exposed	0 / 592 (0.00%)	2 / 294 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fractures and dislocations			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Ischaemic coronary artery disorders			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pericardial disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular arrhythmias			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Central nervous system haemorrhages and cerebrovascular accidents			
subjects affected / exposed	3 / 592 (0.51%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disturbances in consciousness NEC			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurological signs and symptoms NEC			
subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral neuropathies NEC			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Speech and language abnormalities			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient cerebrovascular events			

subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemias NEC			
subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphatic system disorders NEC			
subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenias			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	1 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Inner ear signs and symptoms			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tympanic membrane disorders (excl infections)			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Glaucomas (excl congenital)			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal structural change, deposit and degeneration			

subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal findings abnormal			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernias, site unspecified			
subjects affected / exposed	1 / 592 (0.17%)	4 / 294 (1.36%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute and chronic pancreatitis			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Diarrhoea (excl infective)			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal and small intestinal stenosis and obstruction			
subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspeptic signs and symptoms			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric and oesophageal haemorrhages			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastritis (excl infective)			

subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastrointestinal and abdominal pains (excl oral and throat)		
subjects affected / exposed	11 / 592 (1.86%)	4 / 294 (1.36%)
occurrences causally related to treatment / all	2 / 13	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0
Gastrointestinal atonic and hypomotility disorders NEC		
subjects affected / exposed	3 / 592 (0.51%)	1 / 294 (0.34%)
occurrences causally related to treatment / all	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Gastrointestinal inflammatory disorders NEC		
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastrointestinal necrosis and gangrene (excl gangrenous hernia)		
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastrointestinal stenosis and obstruction NEC		
subjects affected / exposed	14 / 592 (2.36%)	12 / 294 (4.08%)
occurrences causally related to treatment / all	0 / 15	0 / 17
deaths causally related to treatment / all	0 / 0	0 / 2
Large intestinal stenosis and obstruction		
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Nausea and vomiting symptoms		

subjects affected / exposed	3 / 592 (0.51%)	4 / 294 (1.36%)	
occurrences causally related to treatment / all	0 / 5	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-site specific gastrointestinal haemorrhages			
subjects affected / exposed	2 / 592 (0.34%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal and retroperitoneal disorders			
subjects affected / exposed	18 / 592 (3.04%)	6 / 294 (2.04%)	
occurrences causally related to treatment / all	0 / 22	0 / 6	
deaths causally related to treatment / all	0 / 3	0 / 1	
Peritoneal and retroperitoneal fibrosis and adhesions			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis and cholelithiasis			
subjects affected / exposed	1 / 592 (0.17%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis and jaundice			
subjects affected / exposed	1 / 592 (0.17%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Connective tissue disorders			

subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermal and epidermal conditions NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis and eczema			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal failure and impairment			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal obstructive disorders			
subjects affected / exposed	2 / 592 (0.34%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Thyroid disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroid hyperfunction disorders			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Musculoskeletal and connective tissue disorders			
Bone related signs and symptoms			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint related signs and symptoms			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic bone disorders			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue pain and discomfort			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthropathies			
subjects affected / exposed	1 / 592 (0.17%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue disorders NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spine and neck deformities			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations			
Abdominal and gastrointestinal infections			
subjects affected / exposed	2 / 592 (0.34%)	2 / 294 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspergillus infections			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial infections NEC			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dental and oral soft tissue infections			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infections			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes viral infections			
subjects affected / exposed	0 / 592 (0.00%)	2 / 294 (0.68%)	
occurrences causally related to treatment / all	0 / 0	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza viral infections			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract and lung infections			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Sepsis, bacteraemia, viraemia and fungaemia NEC			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Streptococcal infections			
subjects affected / exposed	1 / 592 (0.17%)	3 / 294 (1.02%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infections			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infections			
subjects affected / exposed	3 / 592 (0.51%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular infections			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Appetite disorders			
subjects affected / exposed	1 / 592 (0.17%)	0 / 294 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus (incl subtypes)			
subjects affected / exposed	0 / 592 (0.00%)	1 / 294 (0.34%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Abagovomab	Placebo	
Total subjects affected by non-serious adverse events subjects affected / exposed	532 / 592 (89.86%)	261 / 294 (88.78%)	
Investigations Physical examination procedures subjects affected / exposed occurrences (all)	33 / 592 (5.57%) 46	20 / 294 (6.80%) 33	
Vascular disorders Peripheral vascular disorders NEC subjects affected / exposed occurrences (all)	49 / 592 (8.28%) 62	26 / 294 (8.84%) 35	
Nervous system disorders Headaches NEC subjects affected / exposed occurrences (all) Neurological signs and symptoms NEC subjects affected / exposed occurrences (all) Peripheral neuropathies NEC subjects affected / exposed occurrences (all)	83 / 592 (14.02%) 227 42 / 592 (7.09%) 63 46 / 592 (7.77%) 57	38 / 294 (12.93%) 86 25 / 294 (8.50%) 30 25 / 294 (8.50%) 28	
General disorders and administration site conditions Asthenic conditions subjects affected / exposed occurrences (all) Febrile disorders subjects affected / exposed occurrences (all) Feelings and sensations NEC subjects affected / exposed occurrences (all) General signs and symptoms NEC subjects affected / exposed occurrences (all) Injection site reactions	191 / 592 (32.26%) 431 67 / 592 (11.32%) 111 34 / 592 (5.74%) 42 44 / 592 (7.43%) 75	89 / 294 (30.27%) 240 40 / 294 (13.61%) 73 14 / 294 (4.76%) 25 19 / 294 (6.46%) 25	

subjects affected / exposed occurrences (all)	467 / 592 (78.89%) 4906	222 / 294 (75.51%) 2352	
Oedema NEC subjects affected / exposed occurrences (all)	61 / 592 (10.30%) 82	32 / 294 (10.88%) 39	
Pain and discomfort NEC subjects affected / exposed occurrences (all)	37 / 592 (6.25%) 44	20 / 294 (6.80%) 22	
Gastrointestinal disorders			
Diarrhoea (excl infective) subjects affected / exposed occurrences (all)	98 / 592 (16.55%) 177	41 / 294 (13.95%) 64	
Flatulence, bloating and distension subjects affected / exposed occurrences (all)	45 / 592 (7.60%) 69	25 / 294 (8.50%) 33	
Gastrointestinal and abdominal pains (excl oral and throat) subjects affected / exposed occurrences (all)	183 / 592 (30.91%) 300	81 / 294 (27.55%) 125	
Gastrointestinal atonic and hypomotility disorders NEC subjects affected / exposed occurrences (all)	82 / 592 (13.85%) 115	38 / 294 (12.93%) 54	
Nausea and vomiting symptoms subjects affected / exposed subjects affected / exposed occurrences (all)	130 / 592 (21.96%) 325	64 / 294 (21.77%) 138	
Respiratory, thoracic and mediastinal disorders			
Breathing abnormalities subjects affected / exposed occurrences (all)	48 / 592 (8.11%) 59	23 / 294 (7.82%) 26	
Coughing and associated symptoms subjects affected / exposed occurrences (all)	43 / 592 (7.26%) 51	25 / 294 (8.50%) 31	
Skin and subcutaneous tissue disorders			
Erythemas			

subjects affected / exposed occurrences (all)	40 / 592 (6.76%) 76	22 / 294 (7.48%) 37	
Pruritus NEC subjects affected / exposed occurrences (all)	30 / 592 (5.07%) 50	15 / 294 (5.10%) 16	
Rashes, eruptions and exanthems NEC subjects affected / exposed occurrences (all)	33 / 592 (5.57%) 47	19 / 294 (6.46%) 23	
Psychiatric disorders Disturbances in initiating and maintaining sleep subjects affected / exposed occurrences (all)	31 / 592 (5.24%) 37	17 / 294 (5.78%) 24	
Renal and urinary disorders Bladder and urethral symptoms subjects affected / exposed occurrences (all)	38 / 592 (6.42%) 47	25 / 294 (8.50%) 30	
Musculoskeletal and connective tissue disorders Bone related signs and symptoms subjects affected / exposed occurrences (all)	41 / 592 (6.93%) 59	26 / 294 (8.84%) 44	
Joint related signs and symptoms subjects affected / exposed occurrences (all)	134 / 592 (22.64%) 263	67 / 294 (22.79%) 112	
Muscle pains subjects affected / exposed occurrences (all)	59 / 592 (9.97%) 104	35 / 294 (11.90%) 59	
Musculoskeletal and connective tissue pain and discomfort subjects affected / exposed occurrences (all)	171 / 592 (28.89%) 355	79 / 294 (26.87%) 212	
Infections and infestations Lower respiratory tract and lung infections subjects affected / exposed occurrences (all)	43 / 592 (7.26%) 49	8 / 294 (2.72%) 8	
Upper respiratory tract infections			

subjects affected / exposed	142 / 592 (23.99%)	70 / 294 (23.81%)
occurrences (all)	242	124
Urinary tract infections		
subjects affected / exposed	80 / 592 (13.51%)	27 / 294 (9.18%)
occurrences (all)	114	33

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported